Australis Capital Inc
CNSX:AUSA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (10.1), the stock would be worth CA$-1.19 (4 871% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.2 | CA$0.03 |
0%
|
| Industry Average | 10.1 | CA$-1.19 |
-4 871%
|
| Country Average | 14.4 | CA$-1.7 |
-6 898%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
A
|
Australis Capital Inc
CNSX:AUSA
|
7.5m CAD | -0.2 | -0.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 28.4 | 42 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.6B USD | 16.6 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.6 | 19.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.8B GBP | 16.1 | 29.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.8B CHF | 12.4 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
278.5B USD | 9.5 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8 | 10.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 7.6 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD | 7.1 | 16.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Australis Capital Inc
Glance View
Australis Capital, Inc. operates as a multi-state operator in the cannabis industry in the U.S. The company is headquartered in Las Vegas, Nevada. The company went IPO on 2018-09-18. The firm through its subsidiary 2750176 Ontario Inc. provides in facility design, construction management and (post) commissioning services to the horticultural sector across a range of commercial crops. The company operates horticulture projects across the globe, including the United States, Canada, Denmark Finland, Iceland, Germany, Netherlands, Bahrein, United Arab Emirates, Southeast Asia and Australia. Its subsidiaries include Australis Capital (Nevada) Inc., Australis Holdings LLP, Rthm Technologies Inc., Audacious WR LLC, Australis Perennial LLC, Australis Prosper LLC, Australis Terrain LLC, Coccon Technology LLC, and Australis CA LLC.
